PDR001 (Not yet branded)
Other Medications
Description
PDR001 is a monoclonal antibody that functions as a PD-1 (programmed death-1) checkpoint inhibitor immunotherapy agent. In colorectal cancer treatment, it works by blocking the PD-1 receptor on T-cells, preventing cancer cells from evading immune system detection. Based on clinical trial data, it has been tested in combination with various targeted agents including MEK inhibitors, mTOR inhibitors, and Wnt pathway modulators for enhanced therapeutic efficacy in CRC patients.
Mechanism of Action
PDR001 binds specifically to the PD-1 receptor expressed on activated T-lymphocytes, blocking the interaction between PD-1 and its ligands PD-L1 and PD-L2. This blockade prevents the inhibitory signals that normally suppress T-cell activation, thereby restoring the immune system's ability to recognize and attack colorectal cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | IV |
| Clinical Trials | 5 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.